The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer

Sara Witting Christensen Wen, Rikke Fredslund Andersen, Torben Frøstrup Hansen, Christa Haugaard Nyhus, Henrik Hager, Ole Hilberg, Anders Jakobsen

Research output: Contribution to journalJournal articleResearchpeer-review

21 Downloads (Pure)

Abstract

Background: The homeobox A9 gene encodes a transcription factor, and aberrantly methylated homeobox A9 in the circulation has been suggested as a prognostic marker in early stage non-small cell lung cancer (NSCLC). The aim of the present study was to investigate the prognostic impact of methylated homeobox A9 in plasma from patients with advanced NSCLC.

Methods: Blood samples were prospectively collected from patients with NSCLC stage III and IV receiving standard first line chemotherapy. Sampling took place before treatment initiation and subsequently before each treatment cycle. Plasma was stored at -80 °C until analysis. DNA was extracted, and following bisulfite conversion methylated homeobox A9 was analyzed by methylation specific droplet digital polymerase chain reaction. Detection of methylated homeobox A9 was assessed as a binary variable. The primary endpoint was overall survival (OS).

Results: A total of 231 patients were included. At baseline methylated homeobox A9 was detected in 78.5% of the patients with a clear correlation to survival. The median OS for patients with and without detectable methylated homeobox A9 was 7.4 and 11.1 months, respectively [hazard ratio (HR) 1.79, 95% confidence interval (CI): 1.35-2.38, P<0.001]. The difference increased after the first cycle of treatment. At this time point the median OS was 6.2 and 15.6 months for patients with and without detectable methylated homeobox A9, respectively (HR 2.07, 95% CI: 1.58-2.73, P<0.001). The independent prognostic impact of detectable methylated homeobox A9 after one treatment cycle assessed by multiple Cox regression including known prognostic factors resulted in a HR of 3.79 (2.19-6.54, P<0.001) compared to undetectable methylated homeobox A9.

Conclusions: Measurable methylated homeobox A9 after the first treatment cycle may serve as a valuable prognostic marker in patients with advanced NSCLC. Routine clinical application with treatment reconsideration calls for further studies, preferably in prospective clinical trials.

Original languageEnglish
JournalTranslational Lung Cancer Research
Volume10
Issue number2
Pages (from-to)855-865
ISSN2218-6751
DOIs
Publication statusPublished - Feb 2021

Keywords

  • Biomarkers
  • Circulating tumor DNA
  • HOXA9
  • Methylation
  • Non-small cell lung cancer (NSCLC)

Fingerprint

Dive into the research topics of 'The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this